Integrated Micro-Chromatography Systems (IMCS) is a privately held biotech company that designs, manufactures and distributes biological reagents from recombinant proteins to micro-chromatography products. The genetically modified, industry disrupting IMCSzyme is used by clinical, forensic and pain care laboratories for the drug detection in biological samples. IMCStips are advanced micro-chromatography products centered around patented dispersive solid-phase extraction technology for faster biochemical purification processes. IMCS clients include clinical and forensic toxicology labs, academic research facilities, US federal government agencies and life science companies in North America, Europe and Asia Pacific. Recently, IMCS was awarded an NIH SBIR grant to manufacture glycosyltransferases to leverage its advanced manufacturing and R&D capabilities to expand synthesis of glycosphingolipids and sialoglycans. This provides new product lines and deliver critically needed materials.
IMCS, Inc is presenting as part of the NIH Innovation Zone.